A Gene-Therapy Pioneer Just Filed For Chapter 11 Bankruptcy—Now Eli Lilly Wants Its Tech (opens in new tab)
Sangamo Therapeutics ran out of cash. Eli Lilly and Astellas want the science it spent decades building.
Read the original articleSangamo Therapeutics ran out of cash. Eli Lilly and Astellas want the science it spent decades building.
Read the original article